Compound Profile: Ultima AOD 9604
AOD 9604 is a synthetic peptide fragment comprising the C-terminal portion of human growth hormone, specifically amino acids 176-191. This modified peptide retains the fat-reducing properties of hGH whilst eliminating the growth-promoting effects through targeted structural modifications. Research laboratories utilise this compound to investigate metabolic pathways, adipocyte regulation, and lipolytic mechanisms in controlled experimental environments. The peptide demonstrates unique receptor binding characteristics that make it valuable for examining cellular energy metabolism and adipose tissue dynamics in various research models.
Laboratory Applications
Researchers at Stroid UK Shop investigate AOD 9604’s interactions with growth hormone receptors and its selective binding properties. Studies examine the compound’s effects on lipolysis without corresponding anabolic activity, making it particularly useful for metabolic research. Scientists analyse its impact on fatty acid oxidation pathways, cellular energy expenditure, and adipocyte differentiation in cell culture models. The peptide’s stability profile allows for extended research protocols, whilst its selective mechanism provides insights into growth hormone fragment functionality. Investigations within specialised peptide research frequently compare AOD 9604’s metabolic effects against other growth hormone derivatives and selective modulators. Researchers studying peptide mechanisms evaluate its dose-response relationships, receptor specificity, and potential synergistic effects with other metabolic research compounds.
Technical Specifications
| Parameter | Specification |
|---|---|
| Chemical Name | Human Growth Hormone Fragment 176-191 |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Molecular Weight | 1815.1 g/mol |
| Purity | ≥98% (HPLC verified) |
| Appearance | White lyophilised powder |
| Storage | -20°C (lyophilised), 2-8°C (reconstituted) |
| Solubility | Water, bacteriostatic water |
| Stability | 36 months (unopened, proper storage) |
Research Compliance Statement
This AOD 9604 preparation is manufactured by Ultima Pharmaceuticals exclusively for in-vitro laboratory research applications. The compound is not approved for human consumption, therapeutic use, or any clinical application. Researchers must handle this material in accordance with institutional safety protocols and applicable research regulations. All studies should be conducted within appropriate laboratory facilities by qualified personnel familiar with peptide handling procedures. This product is intended solely for scientific investigation and educational research purposes.
